Skip To Main Content

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden

Living with ITP

Patients reported significant quality of life (QoL) challenges related to their ITP1

Assessing fatigue in ITP patients

For ITP patients, several scales are available to measure and track fatigue and its impact on quality of life. These tools can help patients and healthcare providers gauge symptoms and adjust their ITP treatment accordingly.1-4

Mechanism of Disease

Complex immune dysregulation can lead to autoimmunity and inflammation1-6

EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.

Understanding Disease Modification in Atopic Dermatitis

Act early, think holistically for your patients with Type 2 diabetes at very high cardiovascular risk

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.1 The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.2,3

Understanding Autoimmune T1D & The Value of Early Detection

Autoimmune Type 1 Diabetes (T1D) can be detected through islet autoantibody testing years before symptoms appear.1-2 The video here explains how the condition progresses silently through presymptomatic stages, with beta cell destruction occurring long before symptom onset and clinical diagnosis.4-8

When a Child Gets Autoimmune Type 1 Diabetes

Parent's experiences of stage 3 diagnosis of T1D.

Sleep and QOL: the full impact on patients coping with the burden of AD

Understanding the full scope of AD—the unseen burden on patients.

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

How should individuals with positive autoimmune T1D autoantibodies be monitored over time?

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).1

Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!

Individuals living with other associated autoimmune diseases like celiac disease or autoimmune thyroid disease, are at an increased risk of developing autoimmune type 1 diabetes (T1D) and should be appropriately screened.1-6